Fig. 5

REGN1033 prevents muscle atrophy by immobilization and dexamethasone treatment. a GA muscle weights from mice in which the right hindlimbs were immobilized for 14 days. REGN1033 or isotype control antibody was dosed during the 14-day immobilization period. Results are expressed as the percent change compared to muscle weights of non-immobilized limbs. Statistical significance vs. non-immobilized control is indicated. b TA and GA muscle weights from C57BL/6 mice implanted with osmotic pumps delivering saline or dexamethasone (Dex; 23 μg/day) and simultaneously treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Results are presented as the percent change compared to muscle weights of the saline pump control group. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. c Isometric force as a function of stimulation frequency of TA muscle from mice implanted with osmotic pumps delivering saline or dexamethasone (Dex) and treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. Similar to c but depicting peak tetanic force (d) or specific force (e). All groups had 5–12 animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ^## P < 0.01, ^### P < 0.001, ^#### P < 0.0001